• LAST PRICE
    0.0000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 0.0000
  • Day Range
    ---
  • 52 Week Range
    Low 0.0000
    ---
    High 0.0000
  • Volume
    ---

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
Table Data Not Available
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesARNI
Arno Therapeutics Inc
50.0
0.0x
---
United StatesMLPH
Molecular Pharmacology (USA) Ltd
11.2K
-0.1x
---
United StatesPZRXQ
PZ Wind Down Inc
1.2K
0.0x
---
United StatesNUGX
Nugenerex Immuno-Oncology Inc
1.0K
0.0x
---
United StatesAGGX
Angiogenex Inc
6.1K
0.0x
---
United StatesTLOG
TetraLogic Pharmaceuticals Corp
5.0K
0.0x
---
As of 2023-01-27

Company Information

Arno Therapeutics, Inc. is an early-stage company focused on developing products for the treatment of cancer and other life threatening diseases. The Company's product development pipeline includes Onapristone, AR-42, and AR-12 and analogs. Onapristone is indicated for endometrial, prostate and breast cancer indications. AR-42 is provided for hematological malignancies and solid tumors indications. AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets. Onapristone is a type 1 anti-progestin hormone blocker that has considerable anti-tumor activity in patients with breast cancer. The Company is engaged in developing and commercializing AR-42, which is an oral cancer therapy in early clinical development. AR-42 is a spectrum deacetylase inhibitor of both histone and non-histone proteins, which has potency and activity in solid tumors and hematological malignancies. AR-12 is an orally available cancer treatment.

Contact Information

Headquarters
Suite 104, 200 Route 31 NorthFLEMINGTON, NJ, United States 08822
Phone
862-703-7175
Fax
908-237-0071

Executives

Chairman of the Board
Arie Belldegrun
Chief Executive Officer, Chief Medical Officer, Vice President, Director
Alexander Zukiwski
Chief Development Officer
Stefan Proniuk
Secretary, Director
David Tanen
Director
Jay Moorin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$50.00
Revenue (TTM)
$0.00
Shares Outstanding
49.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.88
EPS
$-0.43
Book Value
$-0.42
P/E Ratio
0.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.